Loading…
Accretion Pharmaceuticals (ACCPL)₹203.15−3.26%Pharmaceuticals
In the Mar 2026 quarter (standalone), Accretion Pharmaceuticals reported sales of ₹45.77 Cr, up 18.2% from Mar 2025, and net profit of ₹4.91 Cr, up 13.9% year on year. For the year to Mar 2026, sales were ₹89.40 Cr and net profit ₹9.65 Cr.
Company filings, standalone accounts; latest reported quarter Mar 2026
| Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Sales | 13.33 | 18.52 | 38.72 | 43.66 | 45.77 |
| Expenses | 10.76 | 14.21 | 31.24 | 36.64 | 37.94 |
| Operating Profit | 2.58 | 4.34 | 7.55 | 7.08 | 7.90 |
| OPM % | 19.2% | 23.3% | 19.4% | 16.1% | 17.1% |
| Other Income | 0.06 | 0.03 | 0.07 | 0.10 | 0.09 |
| Interest | 0.39 | 0.70 | 0.73 | 0.36 | 0.47 |
| Depreciation | 0.21 | 0.36 | 0.40 | 0.39 | 0.80 |
| Profit before tax | 1.99 | 3.28 | 6.46 | 6.40 | 6.66 |
| Tax % | 25.1% | 25.3% | 33.1% | 26.0% | 26.3% |
| Net Profit | 1.48 | 2.45 | 4.31 | 4.74 | 4.91 |
| EPS (Rs) | 3.73 | 3.00 | 5.29 | 4.28 | 4.44 |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Sales | 13.33 | 57.24 | 89.40 |
| Expenses | 10.76 | 45.45 | 74.55 |
| Operating Profit | 2.58 | 11.91 | 14.99 |
| OPM % | 19.2% | 20.7% | 16.6% |
| Other Income | 0.06 | 0.08 | 0.20 |
| Interest | 0.39 | 1.43 | 0.84 |
| Depreciation | 0.21 | 0.76 | 1.20 |
| Profit before tax | 1.99 | 9.75 | 13.06 |
| Tax % | 25.1% | 30.4% | 26.2% |
| Net Profit | 1.48 | 6.77 | 9.65 |
| EPS (Rs) | 3.73 | 8.30 | 8.71 |
| Dividend payout % | 0.0% | 0.0% | 0.0% |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Equity Capital | 4.01 | 8.18 | 11.14 |
| Reserves | 1.48 | 7.10 | 43.51 |
| Borrowings | 13.51 | 14.14 | 12.36 |
| Other Liabilities | 8.49 | 10.53 | 9.68 |
| Total Liabilities | 27.49 | 39.95 | 76.69 |
| Fixed Assets | 5.26 | 6.10 | 13.22 |
| CWIP | 0.00 | 0.00 | 0.19 |
| Investments | 0.00 | 0.00 | 0.00 |
| Other Assets | 22.23 | 33.85 | 63.28 |
| Inventories | 14.47 | 20.60 | 28.36 |
| Trade receivables | 5.79 | 11.65 | 22.37 |
| Cash & equivalents | 0.08 | 0.04 | 4.01 |
| Total Assets | 27.49 | 39.95 | 76.69 |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Cash from operating activity | −11.50 | 5.74 | −14.58 |
| Cash from investing activity | −5.47 | −1.60 | −8.52 |
| Cash from financing activity | 17.05 | −4.17 | 27.09 |
| Net cash flow | 0.10 | −0.05 | 3.99 |
| Capex | 5.47 | 1.60 | 8.52 |
| Free cash flow | −16.93 | 4.12 | −23.08 |
| CFO / OP % | −479.1% | 63.9% | −75.1% |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Debtor days | 158 | 73 | 90 |
| Inventory days | 565 | 189 | 160 |
| Days payable | 255 | 68 | 31 |
| Cash conversion cycle | 465 | 192 | 217 |
| Working capital days | 188 | 64 | 145 |
| ROCE % | — | 46.3% | 28.9% |
For the Mar 2026 quarter, Accretion Pharmaceuticals reported sales of ₹45.77 Cr, up 18.2% year on year and net profit of ₹4.91 Cr, up 13.9% year on year. The operating margin was 17.1%.
Accretion Pharmaceuticals' sales for the year to Mar 2026 were ₹89.40 Cr.
Net profit for the year to Mar 2026 was ₹9.65 Cr. Earnings per share over the same trailing period were ₹8.71.
Accretion Pharmaceuticals reported borrowings of ₹12.36 Cr at Mar 2026, against cash and equivalents of ₹4.01 Cr.
Cash from operations was −₹14.58 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹23.08 Cr.